Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights
  • Choose License Type

Global Anti-epileptic Drugs Market, by Generation (First Generation, Second Generation, Third Generation), By Route of Administration (Oral and Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 6,644.7 million in 2021 and is expected to exhibit a CAGR of 1.4% during the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

Global Anti-epileptic Drugs Market- Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors. The private healthcare sector is one of the sectors, which has been majorly impacted by the COVID-19 pandemic. The lockdown in various countries due to the COVID-19 pandemic has created an economic burden on the private healthcare sectors. A recent study published in the British Medical Journal on April 21, 2021, suggests that people with epilepsy could have a slightly increased risk of being admitted to hospital or dying from coronavirus infection. However, the study does not show whether epilepsy itself causes this increased risk, or whether the risk is linked to other factors that could affect patients with epilepsy. However, management of COVID-19 in people with epilepsy may be more complicated than that in other individuals. COVID-19 treatment drugs and the epilepsy drugs interactions could pose significant challenges and cause cardiac, hepatic, renal problems, which may happen in patients with severe COVID-19 infection, and may require adjustment in the dosages of antiepileptic drugs (AEDs).  Currently, there is no data on the increased incidence of new coronavirus infection (COVID-19) or on the more severe course of the disease in patients with epilepsy.

However, due to the high prevalence of epilepsy among patients after age 60, the increased burden of somatic comorbidities, as well as the need of continuous access to antiepileptic drugs (AED) and care for epilepsy patients, there are several important concerns regarding the management of epilepsy during COVID-19 pandemic.

Thus, impact of the coronavirus (COVID-19) pandemic is expected to limit growth of the global anti-epileptic drugs market during the forecast period.

The increasing number of drug launches is expected to drive the growth of the global anti-epileptic drugs market during the forecast period. For instance, in June 2016, Eisai Co., Ltd. launched Fycompa (perampanel) oral suspension, for the treatment of partial-onset seizures in adult and adolescent patients (aged 12 years and older) suffering from epilepsy.

The increasing prevalence of epilepsy across the globe is expected to drive growth of the anti-epileptic drugs market during the forecast period. For instance, according to the World Health Organization (WHO) report of 2019, around 50 million people worldwide had epilepsy, making it one of the most common neurological diseases globally.

The increasing number of drug approvals from regulatory bodies is expected to drive the global anti-epileptic drugs market growth. For instance, in January 2016, UCB S.A. received European commission (EC) approval for its BRIVIACT (brivaracetam), for the treatment of partial-onset seizure with or without secondary generalization in adults and adolescents patients with epilepsy.

Increasing prevalence of epilepsy in Africa is expected to drive the segment growth over the forecast period. For instance, according to the National Center for Biotechnology Information (NCBI) in 2017, the incidence and prevalence of epilepsy is greatest in Africa, as compared to that of other continents. The incidence of epilepsy is reported to be highest during childhood, with 187 per 100,000 children affected per year, and is highly prevalent among children of the age group 6 -12 years, living in rural areas of Kenya.

 Browse 40 Market Data Tables and 30 Figures spread through 264 Pages and in-depth TOC on Global Anti-epileptic Drugs Market, by Generation (First Generation, Second Generation, and Third Generation), By Route of Administration (Oral and Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Forecast to 2028

To know the latest trends and insights related to Global Anti-epileptic Drugs Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/antiepileptic-drugs-market-1701

The increasing inorganic growth strategies by key players is expected to drive the growth of global anti-epileptic drugs market. For instance, in October 2014, Hikma Pharmaceuticals PLC entered into partnership with Eisai Co., Ltd. for the distribution of Fycompa, Eisai’s first-in-class epilepsy treatment, in the Middle East.

Key Takeaways of the Global Anti-epileptic Drugs Market:

  • The global anti-epileptic drugs market is expected to exhibit a CAGR of 4% during the forecast period (2021-2028), owing to the increasing number of drug launches, which is expected to propel growth of the market during the forecast period. For instance, July 2020, Eisai Co., Ltd. announced that it has launched a new fine granule formulation of its in-house-discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) in Japan. Eisai received the marketing and manufacturing approval for this formulation on January 23, 2020, and the fine granule formulation was added to Japan’s National Health Insurance drug price list on April 23rd of the same year.
  • Among route of administration segment, Oral segment is expected to hold the largest segment due to increasing drug launches. Major key players in the market are also launching generic versions of drugs, which is expected to fuel the oral segment growth in the anti-epileptic drugs market, For instance, in August 2019, Dr Reddy's Laboratories announced the launch of generic anti-epileptic Vigabatrin powder for oral solution in the U.S. market. It is a generic version of Lundbeck's Sabril.
  • Major players operating in global anti-epileptic drugs market are Novartis AG, GlaxoSmithKline Plc., Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Zogenix, Dr. Reddy's Laboratories Ltd., Alkem Labs, SK Biopharmaceuticals, Eisai Co., Ltd., Angelini S.p.a, Sun Pharmaceutical Industries Ltd., UCB S.A, Sanofi S.A., Sumitomo Dainippon Pharma Co., Ltd., and Bausch Health Companies Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner